The Absorption of Needle-Free Insulin Aspart Through Jet Injector in Different Body Parts of Healthy Individuals

What Was Tested

The paper reports a study of Insulin Aspart, published as a randomized controlled trial.

The values of the skin thickness of the abdomen, upper arm, and thigh measured by ultrasonic wave were 2.45 ± 0.34 mm, 2.18 ± 0.50 mm, and 1.93 ± 0.55 mm, respectively.

The hyperinsulin-normal glucose clamp model was successfully established for each subject.

Who Took Part

PubMed indexes the participants as adults, men only.

This randomized, open-label, cross-over trial was conducted on eight healthy adult male volunteers, in which the skin thickness at three injection sites (abdomen, upper arm, and thigh), the time to peak, peak rate, and area under the glucose infusion rate (GIR) curve of plasma insulin were measured through the hyperinsulin-normal glucose clamp test after the injection of insulin aspart with a needle-free syringe at three different sites to analyze the correlation between insulin absorption index at different injection sites and skin thickness.

How the Study Was Run

The researchers set it up as a randomized, open-label and crossover study.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Insulin Aspart study did not mask who received what.

Each person switched between Insulin Aspart and the comparison at some point, usually with a gap in between.

What Was Measured

The values of the skin thickness of the abdomen, upper arm, and thigh measured by ultrasonic wave were 2.45 ± 0.34 mm, 2.18 ± 0.50 mm, and 1.93 ± 0.55 mm, respectively.

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Glucose, Human Body, Insulin and Insulin Aspart.

The authors tagged it with the keywords healthy adult male, hyperinsulin-normal glucose clamp, injection site, insulin absorption and needleless syringe.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Aspart.

The publication is from 2022 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Insulin Aspart compound page, all human trials.